---
schema_version: "secwatch.filing_event.v1"
accession: "0001326190-25-000003"
form_type: "8-K"
ticker: "ALT"
cik: "0001326190"
company_name: "Altimmune, Inc."
filed_at: "2025-02-25T23:59:59+00:00"
generated_at: "2026-05-26T04:30:46.077144+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Altimmune appoints former Dexcom CCO Teri Lawver and ex-Intercept CEO Jerry Durso to board

## Summary
- Board expanded by two to ten; Lawver and Durso appointed effective Feb 24, 2025.
- Lawver, former Dexcom EVP/CCO and J&J Worldwide VP Immunology, brings 30 years pharma/commercial experience.
- Durso, ex-CEO of Intercept Pharmaceuticals and 22-year Sanofi vet, led rare liver disease franchise and acquisition.
- Each director received initial option for 69,800 shares and $40,000 annual cash retainer.
- Appointments support late-stage development and pre-commercial transition for pemvidutide.

## SEC filing metadata
- accession: 0001326190-25-000003
- form_type: 8-K
- ticker: ALT
- cik: 0001326190
- company_name: Altimmune, Inc.
- filed_at: 2025-02-25T23:59:59+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1326190/000132619025000003/0001326190-25-000003-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1326190/000132619025000003/alt-20250224x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001326190-25-000003
- JSON: https://secwatch.observer/filing/0001326190-25-000003.json
- Plain text: https://secwatch.observer/filing/0001326190-25-000003.txt

## Key facts
- Executive change
  Jerome Durso was appointed as Director at Altimmune, Inc..
  - Action: appointed
  - Role: Director
  source text: On February 24, 2025, the Board of Directors (the “Board”) of Altimmune, Inc. (the “Company”), upon the recommendation of the Nominating and Corporate Governance Committee of the Board, increased its size from eight to ten directors and appointed Teri Lawver and Jerome Durso as directors of the Board.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1326190/000132619025000003/0001326190-25-000003-index.htm
- Executive change
  Teri Lawver was appointed as Director at Altimmune, Inc..
  - Action: appointed
  - Role: Director
  source text: On February 24, 2025, the Board of Directors (the “Board”) of Altimmune, Inc. (the “Company”), upon the recommendation of the Nominating and Corporate Governance Committee of the Board, increased its size from eight to ten directors and appointed Teri Lawver and Jerome Durso as directors of the Board.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1326190/000132619025000003/0001326190-25-000003-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.